Norrie Disease (Pseudoglioma) (NDP) Peptide
NDP
Reactivity: Mammalian
Host: Synthetic
BP, IHC, WB
Catalog No. ABIN937500
Quick Overview for Norrie Disease (Pseudoglioma) (NDP) Peptide (ABIN937500)
Target
Norrie Disease (Pseudoglioma) (NDP)
Origin
Mammalian
Source
Synthetic
Application
Blocking Peptide (BP), Immunohistochemistry (IHC), Western Blotting (WB)
-
-
Peptide Type
- Synthetic
-
Sequence
- DPRRCMRHHY VDSISHPLYK CSSKMVLLAR CEGHCSQASR SEPLVSFSTV
-
Characteristics
-
A synthetic peptide for use as a blocking control in assays to test for specificity of NDP antibody,
Alternative Names: NDP control peptide, NDP antibody Blocking Peptide, Anti-NDP Blocking Peptide, Norrie Disease Blocking Peptide, Pseudoglioma Blocking Peptide, EVR2 Blocking Peptide, FEVR Blocking Peptide, ND Blocking Peptide -
Purification
- Rabbit Anti-p44/42 MAP Kinase (Ab-202) Polyclonal Antibody is affinity-purified from rabbit antiserum by affinity chromatography using epitope-specific immunogen.
-
-
-
-
Application Notes
- Optimal conditions should be determined by the investigator
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
-
Buffer
- PBS
-
Handling Advice
- Avoid repeated freeze/thaw cycles.
-
Storage
- -20 °C
-
Storage Comment
- Store at -20 °C long term.
-
-
- Norrie Disease (Pseudoglioma) (NDP)
-
Background
- NDP activates the canonical Wnt signaling pathway through FZD4 and LRP5 coreceptor. NDP plays a central role in retinal vascularization by acting as a ligand for FZD4 that signals via stabilizing beta-catenin (CTNNB1) and activating LEF/TCF-mediated transcriptional programs. NDP acts in concert with TSPAN12 to activate FZD4 independently of the Wnt-dependent activation of FZD4, suggesting the existence of a Wnt-independent signaling that also promote accumulation the beta-catenin (CTNNB1).
-
Molecular Weight
- 15 kDa
Target
-
You are here:
